This article corrects an earlier version that contained inaccurate information. The original said the agreement runs through 2008.
NEW YORK, Nov. 2 (GenomeWeb News) - Invitrogen and Proctor & Gamble Pharmaceuticals have extended a research service agreement through 2006, the firms said today.
The agreement extends a collaboration between the two companies that is several years old.
According to Invitrogen's CEO Greg Lucier, P&GP has been using Invitrogen's RNAi tools such as Stealth, RNAi Gateway, and lentiviral vectors in its target-identification and -validation programs.
Financial details were not discussed.